|
[1]
|
Van Der Helm-Van Mil, A.H., Wesoly, J.Z. and Huizinga, T.W. (2005) Understanding the genetic contribution to rheumatoid arthritis. Current Opinion in Rheumatology, 17, 299-304. doi:10.1097/01.bor.0000160780.13012.be
|
|
[2]
|
Chapuy-Regaud, S., et al. (2005) IgG subclass distribu- tion of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clinical and Experimental Immunol- ogy, 139, 542-550.
doi:10.1111/j.1365-2249.2004.02708.x
|
|
[3]
|
Schellekens, G.A., et al. (1998) Citrulline is an essential constituent of antigenic determinants recognized by rh- eumatoid arthritis-specific autoantibodies. Journal of Cl- inical Investigation, 101, 273-281. doi:10.1172/JCI1316
|
|
[4]
|
Schellekens, G.A., et al.(2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism, 43, 155-163.
doi:10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3
|
|
[5]
|
Nielen, M.M., et al. (2005) Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Annals of the Rheumatic Diseases, 64, 1199-1204. doi:10.1136/ard.2004.029389
|
|
[6]
|
Rantapaa-Dahlqvist, S., et al. (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and Rheumatism, 48, 2741-2749.
doi:10.1002/art.11223
|
|
[7]
|
Cambridge, G., et al. (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis and Rheumatism, 48, 2146-2154.
doi:10.1002/art.11181
|
|
[8]
|
Alessandri, C., et al. (2004) Decrease of anti-cyclic citr- ullinated peptide antibodies and rheumatoid factor fol- lowing anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Annals of the Rheumatic Diseases, 63, 1218-1221.
doi:10.1136/ard.2003.014647
|
|
[9]
|
Atzeni, F., et al. (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citru- llinated peptide antibody titer reduction: A one-year prospective study. Arthritis Research and Therapy, 8, R3.
doi:10.1186/ar1851
|
|
[10]
|
Chen, H.A., et al. (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheuma- toid factor in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 65, 35-39.
doi:10.1136/ard.2005.038851
|
|
[11]
|
Vis, M., et al. (2008) IgM-Rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibri- nogen antibodies decrease during treatment with the tum- or necrosis factor blocker infliximab in patients with rh- eumatoid arthritis. Journal of Rheumatology, 35, 425-428.
|
|
[12]
|
Van Tubergen, A., et al. (2001) Combined spa-exercise therapy is effective in patients with ankylosing spondyli- tis: A randomized controlled trial. Arthritis and Rhe- umatism, 45, 430-438.
doi:10.1002/1529-0131(200110)45:5<430::AID-ART362>3.0.CO;2-F
|
|
[13]
|
Berglin, E., et al. (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Annals of the Rh- eumatic Diseases, 65, 453-458.
doi:10.1136/ard.2005.041376
|
|
[14]
|
Agrawal, S., Misra, R. and Aggarwal, A. (2007) Autoantibodies in rheumatoid arthritis: Association with severity of disease in established RA. Clinical Rheumatology, 26, 201-204.
doi:10.1007/s10067-006-0275-5
|